Results 21 to 30 of about 24,049 (149)

Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival

International Journal of Cancer, EarlyView.
What's New? Patients with esophageal or gastroesophageal junction (GEJ) cancer with residual disease after treatment with neoadjuvant chemoradiotherapy (nCRT) and resection frequently experience poor survival. Improvements in outcome, however, may be possible using adjuvant treatment with nivolumab.
Rob H. A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas Wijnhoven, Mark I. van Berge Henegouwen, Peter S. N. van Rossum, Sarah Derks, Bianca Mostert, Nadia Haj Mohammad, Hanneke W. M. van Laarhoven   +9 more
wiley   +1 more source

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

Med Research, EarlyView.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo   +8 more
wiley   +1 more source

Multifunctional tumor vaccines carrying thalidomide regulate T cell exhaustion and ferroptosis for immunotherapy strategies

VIEW, EarlyView.
MTV can greatly achieved antigen presenting cell (APCs), and THA will be released from the polyplex core and enhanced antigen presenting, thereby prompting APC maturation and antigen presenting. The membrane antigens on MTV are degraded into small peptides by proteasomes and presented by MHC complexes.
Anmin Huang, Ting Li, Ying Zhou, Sihang Li, Jian Zhang, Yingchao Li, Shijia Wu, Yifan Kong, Zhijie Yu, Jinglin Xia   +9 more
wiley   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background Atezolizumab plus bevacizumab (AB) is a standard first‐line therapy for unresectable hepatocellular carcinoma (HCC). However, data on the efficacy and safety of AB rechallenge (re‐AB) after discontinuation are limited. Methods We conducted a retrospective analysis of 13 patients with unresectable HCC who received initial AB ...
Yuichiro Suzuki, Teiji Kuzuya, Leona Osawa, Yasuyuki Komiyama, Hitomi Takada, Shuya Matsuda, Masaru Muraoka, Mitsuaki Sato, Shinya Maekawa, Nobuyuki Enomoto, Hisanori Muto, Yoshihiko Tachi, Yoshiki Hirooka, Atsunori Tsuchiya   +13 more
wiley   +1 more source

Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background and Aims The relationship between oxidative stress (OS) and hepatocellular carcinoma (HCC) is well known, influencing both, hepatocarcinogenesis and subsequent tumor progression. Less understood is its potential role in antitumor defense mechanisms.
Víctor Merino, Carlos Abril, Gloria Segarra, Maria Pilar Ballester, Joan Tosca, Pilar Aguilar, Pascual Medina, Paloma Lluch   +7 more
wiley   +1 more source

Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study

Hepatology Research, EarlyView.
ABSTRACT Aim This study is aimed to evaluate the safety and outcomes of surgical resection in patients with hepatocellular carcinoma (HCC) treated with systemic therapy, address the therapeutic benefit, and identify candidates for surgery after systemic treatment.
Takamichi Ishii, Junichi Shindoh, Ikuo Nakamura, Seiko Hirono, Masaki Wakasugi, Akihiko Ichida, Takashi Hamada, Hajime Matsushima, Takahiro Nishio, Yukio Tokumitsu, Hidenori Takahashi, Yuji Morine, Shinichiro Yamada, Akiyoshi Nakakura, Susumu Eguchi, Kiyoshi Hasegawa, Etsuro Hatano   +16 more
wiley   +1 more source